Spectral Medical Inc.

EDT

CA8475771033

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 02:29:59 11/02/2026 am IST			5-day change	1st Jan Change
1.310 ^CAD	+0.77%		-0.76%	-9.03%

10/12	Spectral Medical Inc. - Special Call
07/11	Spectral Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Spectral Medical Q1 Loss Triples on Fair Value Adjustments

Published on 05/09/2025 at 05:50 pm IST

MT Newswires

Latest news about Spectral Medical Inc.

10/12	Spectral Medical Inc. - Special Call
07/11	Spectral Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
07/11	Spectral Medical Provides Update on PMX Submission to FDA, Also Reports Q3 Loss	MT
07/11	Spectral Medical Brief: Says PMA Submission Targeted for Q1 2026 Following "Positive" Tigris results and ongoing FDA interactions	MT
07/11	Spectral Medical Brief: Total Q3 Revenue Increased to $675,000 compared to $502,000 for the same period in 2024	MT
07/11	Spectral Medical Q3 revenue up 34%	RE
16/25/16	Spectral Medical Provides Observational Study Update	MT
16/25/16	Spectral Medical Inc. Announces Publication of Eden Observational Study	CI
25/25/25	Spectral Medical Receives US$3 Million From Vantive	MT
25/25/25	Spectral Medical receives US$3 million from Vantive	RE
25/25/25	Spectral Medical Brief: Says Received US$3 Million From Vantive	MT
25/25/25	Spectral Medical Inc. announced that it has received $10 million in funding	CI
14/25/14	Spectral Medical Inc. - Special Call
13/25/13	Spectral Medical and Vantive Release Topline Results From Phase 3 Endotoxic Septic Shock Study	MT
13/25/13	Spectral Medical and Vantive Announce Topline Results from Spectral's Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock	CI
08/25/08	Spectral Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
08/25/08	Spectral Medical Q2 Loss Narrows	MT
08/25/08	Spectral Medical announces second quarter and provides corporate update	RE
08/25/08	Earnings Flash (EDT.TO) Spectral Medical Inc. Reports Q2 Revenue C$0.8M	MT
05/25/05	Spectral Medical Higher As Files Base Shelf Prospectus Up to $100 Million, But Says Not a Sign Of Imminent Capital Raising	MT
05/25/05	Spectral Medical announces filing of base shelf prospectus of up to $100 mln	RE
05/25/05	Spectral Medical Brief: Announcing Filing of Base Shelf Prospectus	MT
06/25/06	Spectral Medical Inc. - Shareholder/Analyst Call
15/25/15	Spectral Medical Inc. - Special Call
09/25/09	Spectral Medical Q1 Loss Triples on Fair Value Adjustments	MT

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Companyâ€™s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

Employees

Sector

Pharmaceuticals

Calendar

26/03 - Q4 2025 Earnings Release (Projected)

More about the company